Core Viewpoint - The article emphasizes the urgent need for personalized interventions in the prevention and management of prediabetes, highlighting that not all individuals respond equally to lifestyle changes aimed at reversing prediabetes [5][7][13]. Summary by Sections Diabetes Prevalence and Risks - China faces a severe diabetes prevention and treatment situation, with 140 million diagnosed patients and approximately 500 million individuals in a prediabetic state. Without effective interventions, the risk of developing diabetes in these prediabetic individuals could rise to 95.9% over 30 years [5]. Importance of Personalized Interventions - A recent comprehensive review published in a leading journal indicates that the effectiveness of interventions is closely related to individual characteristics. The study underscores the importance of personalized interventions, as lifestyle changes can significantly vary in effectiveness based on baseline metabolic traits, genetic background, and the extent of lifestyle modifications [7][9]. Meta-Analysis Findings - A meta-analysis involving 31 randomized controlled trials and 236,834 participants found that lifestyle interventions can reduce the risk of progression from prediabetes to type 2 diabetes by 41% (RR 0.59, 95% CI 0.52 – 0.68) and increase the probability of normalizing blood sugar levels by 44% (RR 1.44, 95% CI 1.15 – 1.81) [9][10]. Differential Impact Based on Prediabetes Type - The study revealed that individuals with impaired glucose tolerance (IGT) benefit the most from lifestyle interventions, with a 23% reduction in diabetes risk (RR 0.77, 95% CI 0.64 – 0.93). In contrast, those with isolated impaired fasting glucose (IFG) and non-diabetic hyperglycemia (NDH) showed limited benefits [10][11]. Long-term Effects of Lifestyle Interventions - Long-term follow-up studies indicate that lifestyle interventions can delay the onset of type 2 diabetes by up to 5 years. However, there were no significant differences in cardiovascular disease incidence (HR 0.95, 95% CI 0.73 - 1.24) and all-cause mortality (HR 0.84, 95% CI 0.63 - 1.11) between intervention and control groups [11][12]. Key Insights for Future Interventions - The research highlights the necessity of moving away from a "one-size-fits-all" approach to diabetes prevention, advocating for a precision intervention system based on metabolic profiling. It emphasizes the need to consider individual metabolic characteristics and explore optimal intervention strategies, including exercise intensity and dietary composition [13]. Overall Health Benefits of Lifestyle Changes - While the study confirms individual differences in response to lifestyle interventions, it also stresses that maintaining a healthy lifestyle offers benefits beyond blood sugar control, contributing to overall health, work efficiency, and quality of life [13].

Core Insights - Researchers at Nagoya University have discovered the mechanism by which the antifungal drug Micafungin acts against the bat-derived Porcine Respiratory Virus (PRV), which is significant for addressing disease transmission related to PRV [1][2] Group 1: Research Findings - PRV was first identified in 1968 in bat species and is known to cause acute respiratory diseases in humans, representing a zoonotic pathogen [1] - Micafungin was found to effectively resist PRV, but its specific mechanism of action was previously unclear [1] - The research team identified that Micafungin binds most strongly to the p17 protein of PRV, which is crucial for its function [1] - The addition of Micafungin to PRV-infected human cells resulted in increased expression of genes associated with the interleukin-6 molecular pathway [1] - The use of synthesized p17 antibodies also led to increased expression of the same gene group, indicating a direct relationship between Micafungin and the p17 protein [1] - Suppressing interleukin-6 gene expression with small interfering RNA (siRNA) promoted the formation of syncytia and increased viral particle release [1] - The study concludes that Micafungin inhibits PRV function through its interaction with the p17 protein and the interleukin-6 molecular pathway [1] Group 2: Implications - Micafungin is already approved as a prescription drug in many regions globally, and the findings from this research could aid in managing potential outbreaks of PRV-related infectious diseases in the future [2]